Brief: Everest Medicines Announces European Commission Grants Approval Of Kinpeygo For Adults With Primary IgA Nephropathy To Our Partner Calliditas Therapeutics
18/07/2022 01:17
July 17 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES ANNOUNCES EUROPEAN COMMISSION GRANTS
APPROVAL
OF KINPEYGO® FOR ADULTS WITH PRIMARY IGA NEPHROPATHY TO OUR
PARTNER CALLIDITAS THERAPEUTICS
Source text for Eikon: ID:nPn1mTntpa
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region